Viking Therapeutics is trading 8% down at $38.30 after announcing financing plans that likely increased dilution concerns. - On September 23, 2026, the company announced plans for separate offerings of $200 million in common stock and $200 million in convertible senior notes due 2032. - The decline followed the prior session’s 35.67% rally and came despite positive VK2735 maintenance-study results and a stronger biotechnology sector, indicating company-specific financing pressure is the dominant catalyst.